HOME >> MEDICINE >> NEWS
MSKCC received record gift of $100 million from Mortimer B. Zuckerman for cancer research facility

NEW YORK -- Memorial Sloan-Kettering Cancer Center (MSKCC) today announced a major commitment from publisher, real estate developer, and MSKCC Board member Mortimer B. Zuckerman of $100 million from his charitable trust toward Memorial Sloan-Kettering's new cancer research facility, including a 23-story laboratory structure that opens this month. Mr. Zuckerman's donation is the largest single commitment by an individual in Memorial Sloan-Kettering's history.

When completed, the 693,000 square-foot complex will accommodate a near-doubling in the size of Memorial Sloan-Kettering's research enterprise.

In recognition of his generosity, MSKCC's Boards of Overseers and Managers plan to name the building "The Mortimer B. Zuckerman Research Center."

Mr. Zuckerman was elected a member of Memorial Sloan-Kettering's Board of Overseers in 1991. A native of Canada who holds degrees from McGill University, McGill Law School, The Wharton Graduate School of Business, and Harvard Law School, Mr. Zuckerman is chairman and editor-in-chief of U.S. News and World Report, publisher of the New York Daily News, and the founder of Boston Properties, Inc., one of the largest owners and developers of office properties in the United States. He is also a former associate professor of city and regional planning at the Harvard Graduate School of Design.

"The Mortimer B. Zuckerman Research Center gives vivid physical expression to this institution's role as a leader in cancer research," said MSKCC President Harold Varmus, MD. "The configuration of its laboratories and other spaces will encourage interactions that are critical to productive collaborations among basic scientists and clinical investigators. We are fortunate to have someone like Mort who recognizes the essential connection between scientific discoveries and advances in patient care."

The new building, which includes 16 laboratory floors, is located on East 68th Street between First and
'"/>

Contact: Christine Hickey
mediastaff@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
10-May-2006


Page: 1 2 3 4

Related medicine news :

1. Medical, IT, engineering experts form advisory panel for electronic health record safety
2. Importance of personal health records draws support of American College of Physicians
3. UK record heatwave and rising pollution observed by eyes in the sky: Images reveal hotspots
4. Should patients have to opt out of electronic records?
5. Electronic medical record boosts quality, efficiency
6. Historic records shed light on soldiers lifelong war scars
7. Patients reports of domestic violence not recorded by a nearly a third of surveyed physicians
8. Database of cancer records now available for research
9. Coalitions refusal to record Iraqs civilian deaths failing to respect international law
10. Poland loses record numbers of doctors to the UK
11. Damon Runyon renews its $2.25 million investment to support young clinical cancer investigators

Post Your Comments:
(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: